PIH53 Assessment of PRO Labels Claims Granted by the FDA as Compared to the EMA  by Demuro, C. et al.
entertainment function. The three domains were moderately correlated with each
other (PCC0.5 to 0.6, p0.001). Muscle strength was weakly related with limita-
tions in gross motor function (PCC-0.20, P0.001), and social and entertainment
function (PCC-0.13, P0.001); but not significantly related with limitation in fine
motor function (PCC-0.06, p0.09).CONCLUSIONS:These findings suggest that in
a sample of US elderly aged 60-80 years the NHANES physical function limitation
questionnaire has three domains, of which the gross motor function domain and
social and entertainment function domain are weakly related with muscle
strength.
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OBJECTIVES: To investigate issues in translating a Patient-Reported Outcomes
(PRO) instrument containing idioms and colloquialisms of English-United States
origin. Idiomatic items present an adaptation challenge for translators, generally
requiring additional rounds of discussion and revision. The Linguistic Validation
process allows a local and difficult source to be adapted while maintaining validity
of data when pooling across different countries and cultures. METHODS: Prior to
translation into 25 languages, a survey research expert defined each idiomatic term
in the PRO for the translation team. Additionally, all back-translated documents
were observed to determine the rate and difficulty of revision of idiomatic items,
and cognitive debriefing interviewdata collection formswere analyzed to ascertain
comprehension of adapted idiomatic terms by subjects and to make translation
revisions as needed. RESULTS: As observed, linguists were successful in adapting
the idiomatic source to their target language and culture. Idiomatic items, how-
ever, required an average of two to three revisions, as opposed to non-idiomatic
questions which required one revision or less. For example, “stepping on toes” was
revised two to three times on average across languages, resulting in cultural adap-
tations such as “climbing over others” in Spanish or “trample on others” in Arabic.
Furthermore, when testing the translated instruments, in each instance where a
subject encountered an adapted idiomatic item, it was understood 97.7% of the
time. CONCLUSIONS: A PRO containing English-United States colloquialisms faces
challenges in producing a validated translation. Defining idiomatic items prior to
translation is recommended, as well as repeated discussion, revision and analysis
of back-translated idioms. While idiomatic items can be beneficial to the source
text in terms of patient comprehension, their inclusion is shown to mandate sev-
eral more rounds of discussion and review during the translation process in order
to achieve appropriate levels of conceptual equivalence.
PIH52
ELECTRONIC PATIENT REPORTED OUTCOMES AND DATA TOOL FOR CHRONIC
DISEASE MANAGEMENT (PROCDIM): CASE IN POINT PROSTATE CANCER
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: Patient Reported Outcomes (PROs) play an important role in evaluat-
ing patient quality of life and comparative efficacy of various treatments. Another
potential use of PROs is for chronic diseasemanagement, which can provide useful
data to physicians and patients. We developed a novel web and phone based PROs
tool formanagement of prostate cancer disease.METHODS: PROmethods for pros-
tate cancer were reviewed by analyzing published clinical studies. KOLs and pa-
tient advocacy groups were interviewed to obtain their input for design of PRO
disease management tool. Recent technologies for developing such tools were re-
viewed by analyzing available electronic PRO tools. PROCDIM design was devel-
oped based on secondary research and primary interviews. RESULTS: PROCDIM
was designed to capture patient reported outcomes data such as Quality of Life
(using five attributes), adverse events (six commonly reported AEs), medications
and OTC drugs history, PSA antigen score, past surgery and radiation therapy and
record of physician appointments. Patients could enter data into PROCDIM using
web or phone (iphone or andriod) based systems. Data from PROCDIM could be
emailed by patient to provider or could be downloaded by tethering phone to
computer. Pilot datawas captured by testing PROCDIMwith physicians and patient
advocacy groups. Based on interviews, PROCDIM was rated superior and highly
user friendly compared to current chronic disease management tools. Patient out-
comes datawould be collected fromaplanned IRB approved study.CONCLUSIONS:
PROCDIM is a valuable tool to capture several patients reported outcomes and data
for chronic disease management. Such tools could be used for collecting data for
disease management, clinical trial and for observational studies for various
chronic diseases.
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OBJECTIVES: In 2009, the United States (US) Food and Drug Administration (FDA)
issued a formal guidance for the use of patient-reported outcomes (PRO) in support
of labeling claims, whereas the European Medicines Agency (EMA) offers insight in
a 2007 reflection paper in lieu of formal guidance. To evaluate anddescribe decision
making by the FDA and EMA, a review of PRO label claims granted for new molec-
ular entities and biologic license applications from 2006 through 2010 was con-
ducted. The purpose of this research was to evaluate consistencies and discrepan-
cies and to highlight trends in the acceptance of PRO claims across agencies.
METHODS:A listingwas created of drug approvals granted by both the FDA and the
EMA. PRO claims were compared using US Drug Approval Packages and European
Public Assessment Reports packages to determine any instances where claims
made for the same product by the same company were similar or different.
RESULTS: A total of 75 products were identified as having been approved by both
agencies. Of these, a total of 35 (40%) were granted at least one PRO claim by the
EMA, as comparedwith 14 (19%) by the FDA.Most claims in the US focused on signs
and symptoms; however, claims in the EuropeanUnionweremore likely to include
higher-order concepts such as health-related quality of life (HRQL) and functioning
(29% EMA, 9% FDA). Only a small number of products (10%) had the same claims
granted by both agencies. CONCLUSIONS: The EMA is more likely than the FDA to
grant PRO claims and to grant claims for higher-order constructs such as HRQL and
functioning. Additionally, there appears to be poor concordance between claims
granted by both agencies, which may demonstrate a need for sponsors to develop
agency-specific PRO strategies.
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OBJECTIVES: A recent review (Gnanasakthy, 2012) has shown that about 24% of
New Drug Applications (NDAs) and Biologic License Applications (BLAs) approved
by the Food andDrug Administration (FDA) between 2006 and 2010 had at least one
patient-reported outcome (PRO) label claim, and most claims (74%) were granted
for PRO endpoints that were also primary endpoints. Claims based on primary
endpoints are likely to be fully promoted by the manufacturers; however, the ex-
tent to whichmanufacturers promote claims based on secondary PRO endpoints is
unknown. The purpose of this review is to assess the extent of promotion of PRO
label claims for six products with nonprimary PRO endpoints. METHODS: All six
pharmaceutical products that received PRO label claims based on nonprimary PRO
endpoints between 2006 and 2008 were reviewed. Promotional documents distrib-
uted in the US by themanufacturers of these drugs between the year of launch and
2011 were identified from a PharmaVoxx database. To assess the intensity of pro-
motional activity, circulation of these documents was calculated based on quar-
terly distributions. Two researchers reviewed the documents using standard crite-
ria. Promotional activities based on nonprimary PRO endpoints claims were
compared with total number of messages. Disease-awareness and management
documents and all videos, CDs, and DVD were excluded. RESULTS:Manufacturers
of the six products distributed a total of 973 unique promotional documents 2998
times. Messages based on primary endpoints were distributed 1,798 times,
whereas messages relating to secondary PRO endpoints were distributed 1200
times (40% of distributions), and varied between products (4% to 70%). Messages
relating to PROs were targeted mostly at patients and consumers (65%) and physi-
cians and health care professionals (34%). CONCLUSIONS: Promotion of PRO mes-
sages based on nonprimary endpoints is much lower than those based on primary
endpoints, indicating that manufacturers do not always optimize the potential of
PRO messages.
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OBJECTIVES: ISPOR has focused on patient reported outcomes (PROs) since the
second annual European Congress in 1998, but the prevalence of PROs in product
evaluation for Health Technology Assessments (HTAs) is not well studied. This
study examines the prevalence of PROs for reviews published by nine agencies in
2005-2011: PBAC, CADTH, HAS, IQWiG, SMC, NHS Scotland, NICE, DERP, AHRQ.
METHODS: Analysis of all HTA reports from 2005-2011 in the aforementioned
agencies for 13 disease areas: Alzheimer’s Disease, Anemia in Cancer and Chronic
Kidney Disease, ChronicMyelogenous Leukemia, ClostridiumDifficile, Depression,
Diabetes, Glaucoma, Hepatitis C (adults and pediatrics), HIV (adults and pediatrics),
HPV, Osteoporosis, Ovarian Cancer, Parkinson’s Disease. RESULTS: Among the 324
total reviews from 2005-2011, 91 (28%) reviews report PROs. The use of PROs in-
creased steadily, from 11.1% in 2005 to 42.5% in 2011.We findwide variation across
disease conditions and agencies in the use of PROs. For several disease conditions
there is no use of PROs, but Anemia in Cancer, Ovarian Cancer and Parkinson’s
Disease reviews use PROs at least 75% of the time. Use by agencies varies from 9.8%
(HAS) to 66.7% (IQWiG; NHS Scotland). Reviews of disease conditions are distrib-
uted unequally across agencies and vice versa. This raises the possibility that agen-
cies’ differing use of PROs might simply reflect differences across disease condi-
tions in PRO use, or the reverse. We find evidence that agencies tend to behave
differently depending on the disease condition under review. A significant part of
the variation across agencies arises from their emphasis on different disease
conditions. CONCLUSIONS: HTAs use PROs as an evaluator less than a third of the
time. The use of PROs is steadily increasing over time. Therapeutic area drives the
use of PROs.
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